We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
CONVERSATION WITH THE EXPERTS.
- Abstract
The article offers the information on the drug named as Ibrutinib in the first in the class of Bruton's tyrosine kinase inhibitor approved by U.S. Food and Drug Administration to treat chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL). It lists the adverse events in patients receiving Ibrutinib and presents an interview with Ashley Leak Bryant, who is professor in the School of Nursing at the University of North Carolina, on managing such adverse events.
- Subjects
WASHINGTON (State); ONCOLOGY nursing; CONFERENCES &; conventions; CANCER patients; NURSES; PATIENT education; POSTERS; PROTEIN-tyrosine kinase inhibitors; OCCUPATIONAL roles; ONCOLOGY Nursing Society; PSYCHOLOGY
- Publication
ONS Voice, 2018, Vol 33, Issue 7, p34
- ISSN
2475-6938
- Publication type
Article